Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-In-Human, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Efficacy of ABM-168 Administered Orally in Adult Patients with Advanced Solid Tumors

NCT05831995 is registered in ClinicalTrials.gov with ABM Therapeutics Corporation as lead sponsor.

NCT NCT05831995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05831995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-In-Human, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Efficacy of ABM-168 Administered Orally in Adult Patients with Advanced Solid Tumors
Lead sponsor
ABM Therapeutics Corporation
Phase
Phase 1
Overall status
Terminated
Start date
March 30, 2023
Completion date
June 30, 2024
Enrollment
12 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, nf1 mutation, raf mutation, ras mutation